R
Rafael Morales-Barrera
Researcher at Autonomous University of Barcelona
Publications - 69
Citations - 1441
Rafael Morales-Barrera is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 15, co-authored 56 publications receiving 868 citations. Previous affiliations of Rafael Morales-Barrera include University of Barcelona & Hebron University.
Papers
More filters
Journal ArticleDOI
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
Elena Castro,Nuria Romero-Laorden,Angela del Pozo,Rebeca Lozano,Ana Medina,Javier Puente,Josep M. Piulats,David Lorente,María Isabel Sáez,Rafael Morales-Barrera,Enrique Gonzalez-Billalabeitia,Ylenia Cendon,Iciar García-Carbonero,Pablo Borrega,M. José Mendez Vidal,A. Montesa,Paz Nombela,E. Fernández-Parra,Aranzazu Gonzalez del Alba,José Carlos Villa-Guzmán,Kristina Ibáñez,Alejo Rodriguez-Vida,Lorena Magraner-Pardo,Begoña Perez-Valderrama,Elena Vallespín,Enrique Gallardo,Sergio Vázquez,Colin C. Pritchard,Pablo Lapunzina,David Olmos +29 more
TL;DR: In this paper, a prospective multicenter cohort study evaluated the prevalence and effect of Germline DDR (gDDR) mutations on metastatic castration-resistance prostate cancer (mCRPC) outcomes.
Journal ArticleDOI
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.
Cristina Saura,Desamparados Roda,Susana Roselló,Mafalda Oliveira,Teresa Macarulla,Jose Alejandro Perez-Fidalgo,Rafael Morales-Barrera,Juan Manuel Sanchís-García,Luna Musib,Nageshwar Budha,Jin Zhu,Michelle Nannini,Wai Y. Chan,Sandra Sanabria Bohorquez,Raymond D. Meng,Kui Lin,Yibing Yan,Premal Patel,José Baselga,Josep Tabernero,Andrés Cervantes +20 more
TL;DR: Potent inhibition of AKT signaling with ipatasertib was associated with a tolerable safety profile and meaningful disease control in a subgroup of patients, and Targeting pAKT with an ATP-competitive inhibitor provides a greater therapeutic window than allosteric inhibitors.
Journal ArticleDOI
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
Daniel P. Petrylak,Thomas Powles,Joaquim Bellmunt,Fadi Braiteh,Yohann Loriot,Rafael Morales-Barrera,Howard A. Burris,Joseph Kim,Beiying Ding,Constanze Kaiser,Marcella Fassò,Carol O'Hear,Nicholas J. Vogelzang +12 more
TL;DR: Atezolizumab remained well tolerated and provided durable clinical benefit to a heavily pretreated metastatic urothelial carcinoma population in this long-term study.
Journal ArticleDOI
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
Ali Raza Khaki,Ang Li,Leonidas Nikolaos Diamantopoulos,Mehmet Asim Bilen,Victor Sacristan Santos,John Esther,Rafael Morales-Barrera,Michael Edward Devitt,Ariel Ann Nelson,Christopher J. Hoimes,Evan Shreck,Hussein A. Assi,Benjamin A. Gartrell,Alexander Sankin,Alejo Rodriguez-Vida,Mark F. Lythgoe,David J. Pinato,Alexandra Drakaki,Monika Joshi,Pedro Isaacsson Velho,Noah M. Hahn,Sandy T. Liu,Lucia Alonso Buznego,Ignacio Duran,Marcus Marie Moses,Jayanshu Jain,Jure Murgic,Praneeth Baratam,Pedro C. Barata,Abhishek Tripathi,Yousef Zakharia,Matthew D. Galsky,Guru Sonpavde,Evan Y. Yu,Veena Shankaran,Gary H. Lyman,Gary H. Lyman,Petros Grivas +37 more
TL;DR: It was hypothesized that a poor Eastern Cooperative Oncology Group (ECOG) PS would correlate with shorter overall survival (OS) in patients receiving ICIs.
Journal ArticleDOI
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Antje Neeb,Nicolás Herranz,Sara Arce-Gallego,Susana Miranda,Lorenzo Buroni,Wei Yuan,Alejandro Athie,Teresa Casals,J. Carmichael,J. Carmichael,Daniel Nava Rodrigues,Bora Gurel,Pasquale Rescigno,Pasquale Rescigno,Jan Rekowski,Jon Welti,Ruth Riisnaes,Veronica Gil,Jian Ning,Verena Wagner,Irene Casanova-Salas,Sarai Cordoba,Natalia Castro,Maria de Los Dolores Fenor de la Maza,Maria de Los Dolores Fenor de la Maza,George Seed,Khobe Chandran,Khobe Chandran,Ana Ferreira,Ines Figueiredo,Claudia Bertan,Diletta Bianchini,Diletta Bianchini,Caterina Aversa,Caterina Aversa,Alec Paschalis,Alec Paschalis,Macarena Gonzalez,Rafael Morales-Barrera,Cristina Suarez,Joan Carles,Amanda Swain,Adam Sharp,Adam Sharp,Jesús Gil,Violeta Serra,Christopher J. Lord,Suzanne Carreira,Joaquin Mateo,Johann S. de Bono,Johann S. de Bono +50 more
TL;DR: This data indicates that ATM loss in PC is not always detected by targeted NGS, associates with genomic instability, and is most sensitive to combined ATR and PARP inhibition.